Get the Stockscreener App
5.80
1.36%
-0.08
Entrada Therapeutics Inc stock is traded at $5.80, with a volume of 315.73K.
It is down -1.36% in the last 24 hours and down -18.42% over the past month.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
See More
Previous Close:
$5.88
Open:
$5.82
24h Volume:
315.73K
Relative Volume:
2.20
Market Cap:
$220.13M
Revenue:
$239.40M
Net Income/Loss:
$104.44M
P/E Ratio:
1.9595
EPS:
2.96
Net Cash Flow:
$-18.50M
1W Performance:
-11.31%
1M Performance:
-18.42%
6M Performance:
-56.85%
1Y Performance:
-63.66%
1-Day Range:
$5.62
$5.90
1-Week Range:
$5.62
$6.81
52-Week Range:
$5.62
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
5.80 | 223.17M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Stock (TRDA) Latest News
What are analysts’ price targets for Entrada Therapeutics Inc. in the next 12 monthsWealth Building Watchlist For Every Investor - jammulinksnews.com
Published on: 2025-08-01 20:36:02 - metal.it
Live market analysis of Entrada Therapeutics Inc.Technical Safety Zone Pattern Recognition - Newser
Is Entrada Therapeutics Inc. stock bottoming outDownside Control Plan With Support Analysis - Newser
What moving averages say about Entrada Therapeutics Inc.Support and Resistance Zone Summary Chart - Newser
What are the latest earnings results for Entrada Therapeutics Inc.Low Risk Report For Consistent Profits - jammulinksnews.com
What is the risk reward ratio of investing in Entrada Therapeutics Inc. stockPre Market Entry Points That Work - jammulinksnews.com
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? - Yahoo Finance
Why Entrada Therapeutics Inc. stock attracts strong analyst attentionPortfolio Allocation Strategy for Stability - Newser
New Product Launches: Will They Boost Entrada Therapeutics Inc. Stock in 2025Alpha Focused Technical Trade Signals Gain Attention - metal.it
Volume spikes in Entrada Therapeutics Inc. stock – what they meanFree Access to Real-Time Trade Insights - Newser
Is Entrada Therapeutics Inc. still worth holding after the dipSummary of Consistent Growth Stock Picks - Newser
Can volume confirm reversal in Entrada Therapeutics Inc.Portfolio Risk Distribution Analysis Tool - Newser
How volatile is Entrada Therapeutics Inc. stock compared to the marketMarket Forecast Report For Fast Growth - jammulinksnews.com
Should I hold or sell Entrada Therapeutics Inc. stock in 2025Game-changing capital returns - jammulinksnews.com
What catalysts could drive Entrada Therapeutics Inc. stock higher in 2025Outstanding capital returns - jammulinksnews.com
What institutional investors are buying Entrada Therapeutics Inc. stockMassive portfolio appreciation - jammulinksnews.com
What is the dividend policy of Entrada Therapeutics Inc. stockNavigate market shifts with confidence - jammulinksnews.com
How strong is Entrada Therapeutics Inc. company’s balance sheetSkyrocketing profit margins - jammulinksnews.com
Entrada Therapeutics Inc. Stock Performance After Earnings: Historical InsightsFree Low-Risk Investment Plans - metal.it
How Interest Rate Changes Impact Entrada Therapeutics Inc. Stock PerformanceTop Performer Shortlist - Newser
What makes Entrada Therapeutics Inc. stock price move sharplyFree Stock Selection with 300% Return - Newser
Is Entrada Therapeutics Inc. a good long term investmentHigh-impact stock picks - PrintWeekIndia
What analysts say about Entrada Therapeutics Inc. stockUnbelievable profit margins - Autocar Professional
How high can Entrada Therapeutics Inc. stock price go in 2025Free Stock Market Return Analysis - jammulinksnews.com
Entrada Therapeutics Inc. Stock Analysis and ForecastExceptional financial outcomes - PrintWeekIndia
What drives Entrada Therapeutics Inc. stock priceAccelerated earnings growth - Autocar Professional
How Entrada Therapeutics Inc. stock performs during market volatilityFree Stock Trading Signals - Newser
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):